###begin article-title 0
Calreticulin inhibits commitment to adipocyte differentiation
###end article-title 0
###begin p 1
###xml 31 49 31 49 <email xmlns:xlink="http://www.w3.org/1999/xlink">m.opas@utoronto.ca</email>
Correspondence to Michal Opas: m.opas@utoronto.ca
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 432 435 432 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 435 438 435 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 629 631 629 631 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1159 1161 1143 1145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Calreticulin, an endoplasmic reticulum (ER) resident protein, affects many critical cellular functions, including protein folding and calcium homeostasis. Using embryonic stem cells and 3T3-L1 preadipocytes, we show that calreticulin modulates adipogenesis. We find that calreticulin-deficient cells show increased potency for adipogenesis when compared with wild-type or calreticulin-overexpressing cells. In the highly adipogenic crt-/- cells, the ER lumenal calcium concentration was reduced. Increasing the ER lumenal calcium concentration led to a decrease in adipogenesis. In calreticulin-deficient cells, the calmodulin-Ca2+/calmodulin-dependent protein kinase II (CaMKII) pathway was up-regulated, and inhibition of CaMKII reduced adipogenesis. Calreticulin inhibits adipogenesis via a negative feedback mechanism whereby the expression of calreticulin is initially up-regulated by peroxisome proliferator-activated receptor gamma (PPARgamma). This abundance of calreticulin subsequently negatively regulates the expression of PPARgamma, lipoprotein lipase, CCAAT enhancer-binding protein alpha, and aP2. Thus, calreticulin appears to function as a Ca2+-dependent molecular switch that regulates commitment to adipocyte differentiation by preventing the expression and transcriptional activation of critical proadipogenic transcription factors.
###end p 3
###begin p 4
E. Szabo and Y. Qiu contributed equally to this paper.
###end p 4
###begin p 5
###xml 44 46 44 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Abbreviations used in this paper: CaMKII, Ca2+/calmodulin-dependent protein kinase II; C/EBP, CCAAT enhancer-binding protein; ChIP, chromatin immunoprecipitation; CREB, cAMP response element binding; EB, embryoid body; EMSA, electrophoretic mobility shift assay; ES, embryonic stem; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PPAR, peroxisome proliferator-activated receptor; PPRE, peroxisome proliferator responsive element; RA, retinoic acid; RXR, retinoid X receptor; WT, wild type.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 337 355 337 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">Gesta et al., 2007</xref>
###xml 680 697 680 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib10">Dani et al., 1997</xref>
###xml 886 907 886 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">Gregoire et al., 1998</xref>
###xml 1031 1049 1019 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">Rosen et al., 2000</xref>
###xml 1171 1197 1159 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">Rosen and MacDougald, 2006</xref>
###xml 1245 1247 1233 1235 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1289 1291 1277 1279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1460 1479 1440 1459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">Jensen et al., 2004</xref>
###xml 1481 1511 1461 1491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib51">Serlachius and Andersson, 2004</xref>
###xml 1513 1531 1493 1511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib61">Zhang et al., 2007</xref>
###xml 1579 1581 1559 1561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1650 1673 1630 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">Ntambi and Takova, 1996</xref>
###xml 1675 1691 1655 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">Shi et al., 2000</xref>
###xml 1735 1737 1715 1717 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Obesity is rapidly becoming a worldwide epidemic, leading to numerous medical conditions such as type 2 diabetes and cardiovascular disease. The development of obesity is marked by both an increase in adipocyte size and number as a consequence of differentiation of the stem cells or preadipocytes into mature adipocytes (for review see Gesta et al., 2007). Spontaneous differentiation of embryonic stem (ES) cells into adipocytes in culture is a rare event; thus, for ES cells to commit toward the adipocyte lineage, it is necessary to pretreat cells with retinoic acid (RA), a ligand of the nuclear receptor retinoid X receptor (RXR), during the first phase of differentiation (Dani et al., 1997). RXR in response to RA heterodimerizes with peroxisome proliferator-activated receptor (PPAR), resulting in activation of genes involved in terminal differentiation and lipid metabolism (Gregoire et al., 1998). PPARgamma2, CCAAT enhancer-binding protein alpha (C/EBPalpha), and aP2 are crucial for the development of adipose cells (Rosen et al., 2000). The process of adipogenesis may also be influenced by different extrinsic factor and intracellular signaling pathways (Rosen and MacDougald, 2006), yet very little is known about the role of Ca2+ homeostasis in adipogenesis. Increased Ca2+ levels lead to inhibition of adipocyte differentiation, which is accompanied by the decrease or, in some cases, the loss of PPARgamma2, C/EBPalpha, and aP2 expression (Jensen et al., 2004; Serlachius and Andersson, 2004; Zhang et al., 2007). Thapsigargin, an inhibitor of the sarco/ER Ca2+-ATPase, inhibits adipocyte differentiation in 3T3-L1 preadipocytes (Ntambi and Takova, 1996; Shi et al., 2000), suggesting a role for ER stores and ER Ca2+-binding proteins in the modulation of adipogenesis.
###end p 7
###begin p 8
###xml 26 28 26 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 146 165 146 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">Bedard et al., 2005</xref>
###xml 227 229 227 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 393 395 393 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 416 440 416 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">Baksh and Michalak, 1991</xref>
###xml 442 463 442 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Nakamura et al., 2001</xref>
###xml 511 531 511 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">Mesaeli et al., 1999</xref>
###xml 597 599 597 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 656 658 656 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 760 762 760 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 797 799 797 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 801 822 801 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Nakamura et al., 2001</xref>
###xml 872 874 872 874 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 939 958 939 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">Bedard et al., 2005</xref>
###xml 1122 1124 1122 1124 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Calreticulin is a major Ca2+-buffering protein in the lumen of the ER, which also acts as a molecular chaperone and modulator of gene expression (Bedard et al., 2005). The two major functions of calreticulin, chaperoning and Ca2+ buffering, are confined to specific protein domains. The N+P domain of calreticulin forms a folding module, and the acidic C-terminal C domain binds and buffers Ca2+ with high capacity (Baksh and Michalak, 1991; Nakamura et al., 2001). Calreticulin deficiency is embryonic lethal (Mesaeli et al., 1999), and calreticulin-deficient cells have a reduced capacity for Ca2+ storage within the ER and impaired agonist-stimulated Ca2+ release from ER stores, whereas cells overexpressing calreticulin have higher levels of lumenal ER Ca2+ and a larger pool of releasable Ca2+ (Nakamura et al., 2001). Calreticulin's impact on protein folding and Ca2+ homeostasis have been implicated in several signaling pathways (Bedard et al., 2005), thus affecting gene expression and, consequently, the behavior of individual cells and cell communities. In this study, we show that calreticulin may act as a Ca2+-dependent molecular switch that negatively regulates commitment to adipocyte differentiation by preventing the expression and transcriptional activation of critical proadipogenic transcription factors.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
Calreticulin deficiency promotes adipogenesis
###end title 10
###begin p 11
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 357 365 345 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 467 470 455 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 470 473 458 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 524 527 512 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 527 530 515 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1031 1053 1019 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">Greenspan et al., 1985</xref>
###xml 1135 1161 1123 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">Fowler and Greenspan, 1985</xref>
Fig. 1 A shows that the adipogenic potential of ES cells, as measured by oil red O staining at differentiation day 20 (D20), was approximately30-fold higher in the absence of calreticulin. The number of adipocyte colonies in calreticulin-deficient embryoid bodies (EBs) was approximately ninefold higher than that in the calreticulin-containing EBs at D20 (Fig. 1 B). This was irrespective of whether the calreticulin gene was removed by homologous recombination (G45crt-/- cells) or by Cre recombinase-mediated excision (L7crt-/- cells; Fig. S1 A, available at ). Adipogenesis in ES cells was RA and insulin dependent and required an initial 3-d exposure to RA followed by insulin treatment (unpublished data). Microscopically, by Nile red staining, lipid droplets in the wild-type (WT) adipocytes were indistinguishable from those in calreticulin-deficient cells (Fig. S1 B), indicating that the gross morphology of lipid stores was not affected in the absence of calreticulin. Nile red is a red-emitting fluorescent lysochrome (Greenspan et al., 1985) that can be used as a fluorescent alternative to oil red O lipid visualization (Fowler and Greenspan, 1985). Fig. S2 shows the nucleotide sequence of the calreticulin promoter.
###end p 11
###begin p 12
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Adipogenesis increases in calreticulin-deficient EBs.</bold>
###xml 244 247 244 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 247 250 247 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 257 260 257 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 260 263 260 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 435 438 435 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 438 441 438 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 448 451 448 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 451 454 451 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 860 861 844 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Adipogenesis increases in calreticulin-deficient EBs. Oil red O is a lysochrome used for staining triglycerides and some lipoproteins, thus being useful in visualizing the degree of adipogenesis. (A) At D20, calreticulin-deficient ES cells (G45crt-/- and L7crt-/-) stained more extensively with oil red O than WT cells (P < 0.01; n = 6) and made more adipocyte colonies (P < 0.01; n = 5) (B). (C) The ES cells lacking calreticulin (G45crt-/- and L7crt-/-) showed an increase in expression of PPARgamma2, C/EBPalpha (by Western blotting), and aP2 (by PCR) compared with the WT or L7 cells. Relative protein levels were determined by normalizing the calreticulin, PPARgamma2, and C/EBPalpha to GAPDH, and aP2 mRNA levels were normalized with the housekeeping gene L32. (D) Quantitative analysis of the relative expression of adipogenic markers at D20 (P < 0.01; n = 6). (E) Oil red O staining and Western blot analysis with anticalreticulin (CRT) antibodies of 3T3-L1 preadipocytes and 3T3-L1 cells overexpressing calreticulin (3T3-L1 + CRT). 3T3-L1 cell fibroblasts overexpressing calreticulin showed reduced oil red O staining. (F) RT-PCR showing that adipogenic marker expression decreased in 3T3-L1 + CRT cells overexpressing calreticulin compared with control 3T3-L1 cells. Error bars represent SD.
###end p 12
###begin p 13
###xml 213 216 197 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 210 216 194 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 226 229 210 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 223 229 207 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 254 269 238 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, C and D</xref>
###xml 425 440 409 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, C and D</xref>
###xml 473 481 457 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 928 947 912 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">Otto and Lane, 2005</xref>
###xml 1077 1085 1061 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 E</xref>
###xml 1291 1299 1264 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 F</xref>
Next, we examined the expression of both early (C/EBPalpha and PPARgamma2) and late (aP2) adipogenic markers. The abundance of PPARgamma2 and C/EBPalpha adipogenesis markers was markedly increased at D20 in G45crt-/- and L7crt-/- cells compared with WT (Fig. 1, C and D). The aP2 mRNA levels were undetectable in extracts from the WT and L7 cells, whereas they were high at D20 in extracts from calreticulin-deficient cells (Fig. 1, C and D). It should be stressed that in Fig. 1 C as well as in subsequent figures, adipogenic markers in calreticulin-containing cells are barely discernible. This is caused by a large disparity in the markers' abundance between calreticulin-deficient and calreticulin-containing cells, which makes it difficult to visualize all of them when equally loaded. Modulation of the expression of calreticulin also impacted adipogenesis of 3T3-L1 preadipocytes, a commonly used model for adipogenesis (Otto and Lane, 2005). Increased expression of calreticulin in 3T3-L1 preadipocytes inhibited their adipogenesis, as indicated by oil red O staining (Fig. 1 E). In agreement with ES cell results, molecular markers of adipogenesis (lipoprotein lipase, aP2, PPARgamma2, C/EBPalpha, and C/EBPbeta) were all down-regulated in 3T3-L1 cells overexpressing calreticulin (Fig. 1 F).
###end p 13
###begin p 14
###xml 113 121 113 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 202 217 194 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, B and C</xref>
###xml 263 266 255 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 266 269 258 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 400 415 384 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, B and C</xref>
###xml 613 628 597 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2, D and E</xref>
Upon induction of adipogenesis with RA, the abundance of calreticulin increased dramatically in the WT ES cells (Fig. 2 A), whereas the abundance of PPARgamma2 and C/EBPalpha remained persistently low (Fig. 2, B and C). In contrast, in calreticulin-deficient (G45crt-/-) cells after induction of adipogenesis with RA, PPARgamma2 and C/EBPalpha levels steadily increased over 20 d of differentiation (Fig. 2, B and C). Similar to the WT ES cells, the 3T3-L1 preadipocytes and 3T3-L1 cells overexpressing calreticulin showed an increase in calreticulin abundance and reduced adipogenic potential upon RA treatment (Fig. 2, D and E). We concluded that the increased expression of calreticulin plays a negative regulatory role during adipogenesis.
###end p 14
###begin p 15
###xml 0 159 0 151 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Calreticulin, PPAR&#947;2, and C/EBP&#945; levels increase over the 20-d differentiation time line, whereas overexpression of calreticulin inhibits adipogenesis.</bold>
###xml 250 253 234 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 253 256 237 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 468 470 452 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 644 647 620 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 647 650 623 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
Calreticulin, PPARgamma2, and C/EBPalpha levels increase over the 20-d differentiation time line, whereas overexpression of calreticulin inhibits adipogenesis. (A-C) Calreticulin (CRT), PPARgamma2, and C/EBPalpha expression was examined in WT and G45crt-/- cells by Western blotting over 20 d of adipocyte differentiation as described in Materials and methods. The arrows represent the addition of retinoic acid (RA) or insulin (Ins) and TIT (triiodothyronine). (A) 10-7 M RA treatment of cells during the first 3 d of differentiation induced calreticulin expression in WT cells. (B and C) Expression of PPARgamma2 and C/EBPalpha in RA-treated crt-/- cells gradually increased, whereas their levels in WT cells remained low over the 20-d differentiation. Standard error bars in A-C are smaller than the symbols. RA treatment up-regulates calreticulin in 3T3-L1 cells. (D) Western blot analysis with anti-HA antibodies of 3T3-L1 preadipocytes (3T3-L1 control) and 3T3-L1 cells overexpressing HA-tagged calreticulin (3T3-L1 + CRT) show a marked increase in calreticulin levels after RA treatment. (E) 3T3-L1 cells treated with RA show a decrease in oil red O staining, whereas overexpression of calreticulin reduced the staining further. Error bars represent SD.
###end p 15
###begin title 16
###xml 31 33 31 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Changes in the intracellular Ca2+ concentration affect adipogenesis
###end title 16
###begin p 17
###xml 58 60 58 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 74 95 74 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Nakamura et al., 2001</xref>
###xml 97 116 97 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">Bedard et al., 2005</xref>
###xml 186 188 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 295 297 295 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 308 319 308 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib54">Tsien, 1980</xref>
###xml 343 345 343 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 364 366 364 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 367 371 367 371 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Cyto</sub>
###xml 399 401 399 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 413 434 413 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">Bergling et al., 1998</xref>
###xml 452 454 452 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 455 459 455 459 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Cyto</sub>
###xml 748 750 748 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 789 804 789 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A and B</xref>
###xml 922 925 922 925 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 919 925 919 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 934 937 934 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 931 937 931 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 939 954 939 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A and B</xref>
###xml 1159 1162 1159 1162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1156 1162 1156 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 1172 1175 1172 1175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1169 1175 1169 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 1239 1254 1239 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, A and B</xref>
One important function of calreticulin is modulation of Ca2+ homeostasis (Nakamura et al., 2001; Bedard et al., 2005). Thus, we next examined whether calreticulin-dependent changes in Ca2+ homeostasis might be responsible for modulation of adipogenesis. We used BAPTA-AM, a membrane-permeable Ca2+ chelator (Tsien, 1980), to lower cytosolic Ca2+ concentration ([Ca2+]Cyto) as well as ionomycin, a Ca2+ ionophore (Bergling et al., 1998), to increase [Ca2+]Cyto. Treatment of cells with BAPTA from 20 min to 2 h produced exactly the same results (unpublished data), which implies that BAPTA was not secreted from the cells. BAPTA-AM-treated WT and L7 cells showed a dramatic increase in oil red O staining, indicating that chelation of cytoplasmic Ca2+ promoted adipogenesis in these cells (Fig. 3, A and B). There was no significant increase in oil red O staining in BAPTA-AM-treated calreticulin-deficient ES cells (G45crt-/- or L7crt-/-; Fig. 3, A and B). In contrast, after treatment with ionomycin, there was no detectable oil red O-positive adipocytes derived from WT and L7 cells, whereas differentiation of both calreticulin-deficient cell lines (G45crt-/- and L7crt-/-) produced an extremely low number of oil red O-positive cells (Fig. 3, A and B).
###end p 17
###begin p 18
###xml 27 29 27 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Changes in intracellular Ca<sup>2+</sup> concentration affect adipogenesis.</bold>
###xml 98 100 98 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 141 143 141 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 171 173 171 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 412 415 412 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 415 418 415 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 425 428 425 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 428 431 428 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 594 595 594 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 822 825 814 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 825 828 817 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 835 838 827 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 838 841 830 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 953 954 945 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1065 1066 1057 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Changes in intracellular Ca2+ concentration affect adipogenesis. BAPTA-AM, a membrane-permeable Ca2+ chelator, was used to lower cytosolic Ca2+ concentration, whereas a Ca2+ ionophore, ionomycin, was used to increase it. (A) WT and L7 ES cells showed increased oil red O staining after treatment with BAPTA-AM, whereas no substantial change in the staining was discernible in calreticulin-deficient ES cells (G45crt-/- and L7crt-/-). Ionomycin treatment decreased oil red O staining in calreticulin-deficient cells. (B) Colorimetric assay of oil red O staining in the ES cells treated as in A (n = 6). (C) Treatment with BAPTA-AM increased the expression of PPARgamma2, C/EBPalpha, and aP2 in WT or L7 ES cell lines. Conversely, ionomycin treatment decreased the adipogenic marker expression in calreticulin-deficient (G45crt-/- and L7crt-/-) cells. (D) Quantitative analysis of relative adipogenic marker expression after BAPTA-AM treatment (P < 0.01; n = 6). (E) Quantitative analysis of relative adipogenic marker expression after ionomycin treatment (P < 0.01; n = 6). Error bars represent SD.
###end p 18
###begin p 19
###xml 294 297 294 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 297 300 297 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 307 310 307 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 310 313 310 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 325 340 325 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, C and D</xref>
###xml 482 497 474 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, C and E</xref>
###xml 657 660 641 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 654 660 638 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 670 673 654 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 667 673 651 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 683 698 667 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, C and E</xref>
In agreement with oil red O staining results, BAPTA-AM treatment significantly increased the abundance of all three adipogenic markers in adipocytes derived from WT and L7 cells containing calreticulin but did not have a significant effect on adipocytes derived from calreticulin-deficient (G45crt-/- and L7crt-/-) ES cells (Fig. 3, C and D). In the presence of ionomycin, the levels of PPARgamma2, C/EBPalpha, and aP2 remained nearly undetectable in extracts from WT and L7 cells (Fig. 3, C and E). However, ionomycin significantly decreased the abundance of PPARgamma2, C/EBPalpha, and aP2 levels in extracts from calreticulin-deficient cell lines (G45crt-/- and L7crt-/-) at D20 (Fig. 3, C and E).
###end p 19
###begin title 20
Modulation of adipogenesis by functional modules of calreticulin
###end title 20
###begin p 21
###xml 56 77 56 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Nakamura et al., 2001</xref>
###xml 131 133 131 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 145 153 145 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 374 377 374 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 377 380 377 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 544 565 544 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Nakamura et al., 2001</xref>
###xml 632 640 632 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
Calreticulin has two structural and functional domains (Nakamura et al., 2001); one responsible for chaperoning, and another for Ca2+ buffering (Fig. 4 A). To determine which of calreticulin's functions (domains) may be involved in the modulation of adipogenesis, two ES cell lines expressing single functional modules of calreticulin in calreticulin-deficient ES cells (G45crt-/-) were created and tested for adipogenic potential. Because the C domain of calreticulin cannot be stably maintained, it was fused to the P domain of calreticulin (Nakamura et al., 2001). Expression of the domains was tracked using anti-HA antibodies (Fig. 4 A).
###end p 21
###begin p 22
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of the P+C domains of calreticulin reduces adipogenesis.</bold>
###xml 203 206 203 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 206 209 206 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 303 306 303 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 306 309 306 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 318 321 318 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 321 324 321 324 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 369 372 369 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 372 375 372 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 451 454 451 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 454 457 454 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 695 698 695 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 698 701 698 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 801 804 801 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 804 807 804 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1157 1160 1157 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 1160 1163 1160 1163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1196 1199 1196 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 1199 1202 1199 1202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1220 1221 1220 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1361 1362 1361 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1445 1448 1445 1448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 1448 1451 1448 1451 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1493 1494 1493 1494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1530 1533 1530 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 1533 1536 1533 1536 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1637 1638 1637 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1649 1651 1649 1651 <sup xmlns:xlink="http://www.w3.org/1999/xlink">45</sup>
###xml 1653 1655 1653 1655 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1754 1756 1754 1756 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1805 1808 1805 1808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 1808 1811 1808 1811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1832 1834 1832 1834 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1835 1837 1835 1837 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ER</sub>
###xml 1845 1847 1845 1847 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1848 1851 1848 1851 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Tot</sub>
###xml 1864 1867 1864 1867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 1867 1870 1867 1870 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1878 1879 1878 1879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1989 1991 1989 1991 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2026 2029 2026 2029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 2029 2032 2029 2032 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2053 2055 2053 2055 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2056 2058 2056 2058 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ER</sub>
###xml 2083 2085 2083 2085 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2099 2102 2099 2102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 2102 2105 2102 2105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2113 2114 2113 2114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 2125 2127 2125 2127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">45</sup>
###xml 2129 2131 2129 2131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2210 2212 2210 2212 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2213 2215 2213 2215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ER</sub>
###xml 2223 2225 2223 2225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2226 2229 2226 2229 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Tot</sub>
###xml 2338 2340 2338 2340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2341 2344 2341 2344 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Tot</sub>
###xml 2352 2354 2352 2354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2355 2357 2355 2357 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ER</sub>
###xml 2389 2390 2389 2390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Expression of the P+C domains of calreticulin reduces adipogenesis. (A) A schematic of the structural and functional calreticulin domains as well as Western blot analysis (with anti-HA antibodies) of G45crt-/- ES cells expressing the N+P and P+C domain of calreticulin. (B) Oil red O staining in WT, G45crt-/-, and G45crt-/- ES cells expressing P+C and N+P domains. G45crt-/-cells expressing the P+C domain had decreased staining compared with the G45crt-/- cells. When the cells were treated with 50 nM BAPTA-AM, both the P+C domain-expressing and WT ES cells showed a dramatic increase in oil red O staining. The N+P domain-expressing ES cells had oil red O staining similar to that of the G45crt-/- ES cells. When the cells were treated with 500 nM ionomycin, both the N+P domain-containing and G45crt-/- ES cells showed a decrease in oil red O staining. (C) Expression of the P+C domain in 3T3-L1 cells (3T3-L1 + [P+C]) reduced oil red O staining. Because 3T3-L1 is used as a control, it is always counted as 1. Expression of the P+C domain was confirmed using HA antibody. (D) Adipogenic marker expression was decreased in the P+C domain-containing G45crt-/- cells when compared with the G45crt-/- cells (P < 0.01; n = 6) and was comparable to that in WT cell levels (P > 0.05). BAPTA-AM treatment increased adipogenic marker expression in all cell lines (n = 6). (E) Adipogenic marker expression was higher in the N+P domain-expressing G45crt-/- cells than in the WT ES cells (P < 0.01; n = 6) and was similar to that in G45crt-/- cell levels (P > 0.05). Ionomycin treatment reduced adipogenic marker expression in all cell lines (n = 6). (F) 45Ca2+-loaded ES cells were treated with thapsigargin or ionomycin to measure ER-releasable and total [Ca2+], respectively. WT and P+C domain-expressing G45crt-/- cells had higher [Ca2+]ER and [Ca2+]Tot than the G45crt-/- cells (n = 3). (G) Fura-2-AM-loaded ES cells were treated with thapsigargin to measure ER-releasable and cytosolic [Ca2+]. WT and P+C domain-expressing G45crt-/- cells had higher [Ca2+]ER and higher cytosolic [Ca2+] than the G45crt-/- cells (n = 3). (H) 45Ca2+-loaded 3T3-L1 cells were treated with thapsigargin or ionomycin to measure [Ca2+]ER and [Ca2+]Tot levels. 3T3-L1 + CRT cells (overexpressing calreticulin) and 3T3-L1 expressing the P+C domain had higher [Ca2+]Tot and [Ca2+]ER than the control 3T3-L1 cells (n = 3). Error bars represent SD.
###end p 22
###begin p 23
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 107 122 107 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, B and D</xref>
###xml 221 229 221 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
###xml 274 277 274 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 271 277 271 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 338 353 338 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, B and D</xref>
###xml 404 407 404 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 401 407 401 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 569 577 569 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 646 652 646 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 776 779 776 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 773 779 773 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 870 873 870 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 867 873 867 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 892 895 892 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 895 898 895 898 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 922 924 922 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1084 1086 1084 1086 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Fig. 4 B shows that reexpression of the P+C domain in calreticulin-deficient cells inhibited adipogenesis (Fig. 4, B and D). Overexpression of the P+C domain in 3T3-L1 preadipocytes also resulted in reduced adipogenesis (Fig. 4 C). Treatment of the P+C domain-expressing crt-/- ES cells with BAPTA-AM restored their adipogenic potential (Fig. 4, B and D). In contrast, expression of the N+P domain in crt-/- ES cells had no significant effect on their ability to differentiate into adipocytes, and they maintained a phenotype identical to calreticulin-deficient cells (Fig. 4 B). This was further supported by BATPA-AM and ionomycin experiments (Fig. 4), indicating that the chaperone function of calreticulin was not involved in the modulation of adipogenesis. Therefore, crt-/- cells expressing the N+P domain of calreticulin displayed features resembling those of crt-/- ES cells, whereas crt-/- cells expressing the Ca2+-buffering region of the protein (P+C domain) had properties characteristic of those of WT cells, indicating that calreticulin modulates adipogenesis via its Ca2+ homeostatic function.
###end p 23
###begin p 24
###xml 24 26 24 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 138 140 138 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 232 234 232 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">45</sup>
###xml 236 238 236 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 320 322 320 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">45</sup>
###xml 324 326 324 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 349 351 349 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 457 459 457 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 532 534 532 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 570 572 570 572 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 621 623 621 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 645 653 645 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 F</xref>
###xml 666 674 666 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 H</xref>
###xml 718 720 718 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 773 775 773 775 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 798 800 798 800 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 822 837 822 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4, F and H</xref>
###xml 893 895 893 895 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1025 1027 1025 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1028 1030 1028 1030 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ER</sub>
###xml 1038 1040 1038 1040 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1041 1044 1041 1044 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Tot</sub>
###xml 1081 1084 1081 1084 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1078 1084 1078 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 1095 1103 1095 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 F</xref>
###xml 1156 1158 1156 1158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1195 1197 1195 1197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1240 1242 1240 1242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1256 1258 1256 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1354 1371 1354 1371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">Mery et al., 1996</xref>
###xml 1374 1382 1374 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 G</xref>
###xml 1506 1508 1506 1508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1509 1511 1509 1511 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ER</sub>
###xml 1519 1521 1519 1521 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1522 1526 1522 1526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Cyto</sub>
###xml 1566 1569 1566 1569 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1563 1569 1563 1569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 1713 1715 1713 1715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1716 1718 1716 1718 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ER</sub>
###xml 1726 1728 1726 1728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1729 1732 1729 1732 <sub xmlns:xlink="http://www.w3.org/1999/xlink">Tot</sub>
###xml 1769 1777 1769 1777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 H</xref>
###xml 1833 1835 1833 1835 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1942 1944 1942 1944 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2011 2014 2011 2014 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 2008 2014 2008 2014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 2102 2104 2102 2104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 2276 2278 2276 2278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
To assess whether the Ca2+ content of intracellular Ca2+ stores is modified in crt-/- cells and calreticulin-deficient cells expressing Ca2+ handling the P+C domain of calreticulin, we performed equilibrium loading experiments with 45Ca2+. Cells were cultured for 54 h in the regular culture medium containing 10 mCi/ml 45Ca2+. The total cellular Ca2+ content was then calculated based on the cell-associated radioactivity and on the specific activity of Ca2+ in the culture medium. We used thapsigargin, an inhibitor of sarco/ER Ca2+-ATPase, to measure the amount of Ca2+ associated with ER-exchangeable intracellular Ca2+ stores in either ES (Fig. 4 F) or 3T3-L1 (Fig. 4 H) cells. To assess the residual amount of Ca2+ contained within thapsigargin-insensitive lumenal Ca2+ stores, we used the Ca2+ ionophore ionomycin (Fig. 4, F and H). Measurement of ionomycin- and thapsigargin-induced Ca2+ discharge from the ER indicated that the WT ES cells and calreticulin-deficient ES cells expressing the P+C domain had higher [Ca2+]ER and [Ca2+]Tot, respectively, compared with the crt-/- ES cells (Fig. 4 F). To provide yet another measure of ER-releasable Ca2+, we measured thapsigargin-induced Ca2+ discharge from the ER versus cytosolic [Ca2+] using the Ca2+-sensitive fluorescent dye fura-2-AM under conditions preventing dye sequestration into the ER (Mery et al., 1996). Fig. 4 G shows that calreticulin-containing WT ES cells and calreticulin-deficient ES cells expressing the P+C domain had higher [Ca2+]ER and [Ca2+]Cyto, respectively, in comparison to the crt-/- ES cells. Similar to the ES cells, overexpression of calreticulin or the P+C domains in the 3T3-L1 preadipocytes also resulted in increased [Ca2+]ER and [Ca2+]Tot compared with control 3T3-L1 cells (Fig. 4 H). Finally, as ionomycin may be inactive in releasing Ca2+ from acidic intracellular compartments, we added the sodium proton ionophore monensin. Monensin-induced Ca2+ release was very small (unpublished data), suggesting that WT, crt-/- cells, and cells expressing the N+P domain did not contain substantial quantities of Ca2+ stored within acidic compartments. Thus, we conclude that the effects of calreticulin on adipogenesis may be mediated by calreticulin-dependent changes in intracellular Ca2+.
###end p 24
###begin title 25
Functional relationship between calreticulin and PPARgamma2
###end title 25
###begin p 26
###xml 554 562 542 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 861 869 837 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 1083 1091 1056 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 1121 1129 1094 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
The results so far suggested that calreticulin plays a modulatory role during adipogenesis. We next wanted to determine whether there was a functional relationship between calreticulin and the PPARgamma transcriptional complex. Upon RA-dependent induction of adipogenesis, RXR and PPARgamma form a transcriptionally active complex. The calreticulin promoter contains two PPARgamma-binding sites termed peroxisome proliferator responsive elements (PPREs); one is found at -1,944 bp (designated PPRE1), and the other is found at -590 bp (designated PPRE2; Fig. 5 A), suggesting that the PPARgamma transcription factor may regulate the calreticulin gene. To test this, NIH3T3 fibroblasts were cotransfected with PPARgamma expression vector and RXRalpha expression vector (pLC0, pLC1, pLC2, pLC0mt1, and pLC0mt2) or luciferase reporter gene vectors (pCL2 and pCL3; Fig. 5 A) under control of the calreticulin promoter. pSVbeta-galactosidase was used as an internal control. In the pLC0 vector, luciferase was controlled by 2.1 kb of the calreticulin promoter containing both PPRE sites (Fig. 5 A and Fig. S2, available at ). Fig. 5 B shows that PPARgamma induced luciferase activity in NIH3T3 cells. Cells transfected with promoterless control plasmids showed no detectable luciferase activity (unpublished data). This finding indicates that PPARgamma activates transcription of the calreticulin gene.
###end p 26
###begin p 27
###xml 0 42 0 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">PPAR&#947; activates the calreticulin gene.</bold>
###xml 1636 1641 <span type="species:ncbi:10090">mouse</span>
PPARgamma activates the calreticulin gene. (A) A schematic representation of reporter plasmids used in this study. The calreticulin promoter (pLCC0) contains two PPRE sites: PPRE1 (-1,944 bp) and PPRE2 (-590 bp). Two promoter deletion constructs (pLC1 and pLC2) and two promoter constructs, one containing a mutation of PPRE1 (pLC0mt1) and the other containing a mutation of PPRE2 (pLC0mt2), were used to identify PPRE sites activated by PPARgamma on the calreticulin promoter. (B) To analyze the effect of PPARgamma and RXRalpha on the calreticulin promoter, NIH3T3 cells were transiently cotransfected with the PPARgamma and RXRalpha expression plasmids with a luciferase reporter gene controlled by the calreticulin promoter as indicated in A. Individual controls were obtained for each expression plasmid, and data were plotted relative to that control (luciferase/beta-galactosidase). The data shown are mean +/- SD (error bars) of three independent experiments. (C) EMSA analysis was performed to demonstrate the binding of PPARgamma to the PPRE1 and PPRE2 elements on calreticulin promoter. The positions of PPARgamma-RXRalpha-DNA complexes are indicated. White lines indicate that intervening lanes have been spliced out. (D) Supershift EMSA analysis of PPARgamma binding to the PPRE1 and PPRE2 elements on calreticulin promoter using anti-HA tag antibody was used to show the binding of transcriptional factor to the DNA element. Mutated PPRE1 and PPRE2 oligonuleotide show no interaction with PPARgamma. Arrows mark PPARgamma complexes with either PPRE1 or PPRE2. (E) ChIP analysis of a putative PPARgamma-binding site in the mouse calreticulin promoter was used to show binding of PPARgamma to the endogenous calreticulin promoter. Lane 1 shows input DNA, lane 2 is a negative control without antibody treatment, and lane 3 shows ChIP with antibodies.
###end p 27
###begin p 28
###xml 154 169 150 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, B and C</xref>
###xml 302 310 294 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 B</xref>
###xml 351 359 343 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 394 402 386 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 459 474 447 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, B and C</xref>
To identify the PPARgamma-binding site on the calreticulin promoter, we performed reporter gene assay with calreticulin promoter deletions and mutations (Fig. 5, B and C). Deletion of PPRE1 and PPRE2 sites (pLC2 vector) completely abolished PPARgamma-dependent activation of the calreticulin promoter (Fig. 5 B). Deletion of PPRE site 2 at -1,944 bp (Fig. 5 A) or mutation of PPRE site 1 or 2 (Fig. 5 A) had no effect on PPARgamma activation of the promoter (Fig. 5, B and C). Thus, upon induction of adipogenesis with RA, RXR and PPARgamma form a complex, which binds PPRE sites 1 and 2 on the calreticulin promoter and transcriptionally activates the calreticulin gene.
###end p 28
###begin p 29
###xml 155 163 151 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 301 309 297 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 529 537 505 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 693 701 661 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 755 763 723 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 841 849 809 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 C</xref>
###xml 1048 1056 1016 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 D</xref>
###xml 1318 1326 1278 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 E</xref>
To further elucidate a physical interaction between the calreticulin promoter and PPARgamma, an electrophoretic mobility shift assay (EMSA) was performed (Fig. 5 C). Synthetic oligodeoxynucleotides corresponding to PPRE sites 1 and 2 were used along with a positive control probe, an ideal PPAR site. Fig. 5 C shows that the PPARgamma-RXRalpha complex bound to PPRE1 and PPRE2. This DNA-protein interaction was only observed in the presence of RXRalpha, indicating that PPARgamma is only functional once complexed with RXRalpha (Fig. 5 C). The specificity of the PPRE and PPARgamma-RXRalpha binding was confirmed by reduced signal intensity after the addition of 30-fold excess of cold probe (Fig. 5 C). The lesser intensity in PPRE1 and PPRE2 complexes (Fig. 5 C, lanes 4 and 6) when compared with complexes containing the ideal PPRE site (Fig. 5 C, lanes 1, 3, and 10) is likely the result of the different nucleotide sequences of these probes. Specificity of the binding was further confirmed by supershift EMSA and mutation of both PPRE sites (Fig. 5 D). Chromatin immunoprecipitation (ChIP) was also performed to determine whether there was a direct interaction between the calreticulin promoter and PPARgamma. ChIP analysis indicated that PPARgamma bound to both PPRE sites 1 and 2 on the calreticulin promoter (Fig. 5 E). We concluded that the PPARgamma-RXRalpha complex binds to calreticulin PPRE1 and PPRE2 sites and activates the calreticulin gene.
###end p 29
###begin p 30
###xml 86 97 78 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">Rosen, 2005</xref>
###xml 99 125 91 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">Rosen and MacDougald, 2006</xref>
###xml 201 219 189 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">Rosen et al., 2000</xref>
###xml 302 308 290 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6</xref>
###xml 344 347 332 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 347 350 335 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 435 443 419 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 532 540 512 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 639 647 619 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
PPARgamma2, along with C/EBPalpha, directly affect gene transcription in the nucleus (Rosen, 2005; Rosen and MacDougald, 2006). Given that PPARgamma2 is both necessary and sufficient for adipogenesis (Rosen et al., 2000), we determined its spatial expression during adipogenesis in our ES cell system (Fig. 6). On D20 of differentiation in the crt-/- ES cells (which exhibit increased adipogenesis), PPARgamma2 was distinctly nuclear (Fig. 6 A). However, in the WT ES cells, PPARgamma2 was barely detectable and appeared cytosolic (Fig. 6 B). Given that the WT ES cells show reduced adipogenesis and, thus, only sparse adipocyte colonies, Fig. 6 B represents a region of low adipogenic potential that predominates in WT outgrowths. Localization of C/EBPalpha was also investigated in the ES cells, and it showed an essentially identical pattern to that observed for PPARgamma2 (unpublished data).
###end p 30
###begin p 31
###xml 0 96 0 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">PPAR&#947;2 localization in calreticulin-deficient G45 and calreticulin-expressing CGR8 ES cells.</bold>
PPARgamma2 localization in calreticulin-deficient G45 and calreticulin-expressing CGR8 ES cells. At D20 of differentiation, the cells were labeled for PPARgamma2 and propidium iodide (PI) to identify the nuclei as described in Materials and methods. (A) In the calreticulin-deficient cells, PPARgamma2 (green) colocalized with propidium iodide (red). (B) In the calreticulin-containing cells, labeling for PPARgamma2 was barely detectable and perinuclear. Bar, 25 mum.
###end p 31
###begin title 32
Calmodulin/CaMKII, CREB, and calcineurin during adipogenesis
###end title 32
###begin p 33
###xml 13 15 13 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 134 151 134 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">Wang et al., 1997</xref>
###xml 153 172 153 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">Reusch et al., 2000</xref>
###xml 369 372 369 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 372 375 372 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 385 388 385 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 462 477 462 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, A and B</xref>
###xml 568 571 568 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 571 574 571 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
Calmodulin-Ca2+/calmodulin-dependent protein kinase II (CaMKII) and cAMP response element binding (CREB pathways affect adipogenesis (Wang et al., 1997; Reusch et al., 2000). Western blot analysis with anti-Thr286-phosphorylated CaMKII, anticalmodulin, and anti-Ser133-phosphorylated CREB antibodies showed that their expression was higher in calreticulin-deficient G45crt-/- and L7crt-/- cells than in WT and L7 cells at the end of the 20 d of differentiation (Fig. 7, A and B). These results indicate that CaMKII and CREB play a positive role during adipogenesis of crt-/- cells and that they are up-regulated in the absence of calreticulin.
###end p 33
###begin p 34
###xml 0 91 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Calmodulin, CaMKII, and CREB expression is up-regulated in calreticulin-deficient ES cells.</bold>
###xml 103 106 103 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 106 109 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 116 119 116 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 119 122 119 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 355 356 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 442 445 441 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 445 448 444 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 455 458 454 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 458 461 457 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 708 709 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1085 1086 1060 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1277 1280 1252 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 1280 1283 1255 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1327 1328 1302 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1614 1615 1589 1590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Calmodulin, CaMKII, and CREB expression is up-regulated in calreticulin-deficient ES cells. (A) The G45crt-/- and L7crt-/- cells had increased calmodulin, phosphorylated CaMKII (Thr286), and phosphorylated CREB (pSer133) expression when compared with WT and L7 cells. (B) Quantitative analysis of the expression of calmodulin, CaMKII, and CREB (P < 0.01; n = 6). (C) 10 muM KN-62 and KN-93 reduced oil red O staining in calreticulin-null (G45crt-/- and L7crt-/-) cells. Treatment of cells with KN-92, an inactive analogue of KN-93, had no effect on oil red O staining. (D) Colorimetric analysis showed a significant decrease in oil red O staining in calreticulin-null cells upon CaMKII inhibition (P < 0.01; n = 6). (E) Western blot analysis of PPARgamma2, C/EBPalpha, and aP2 after inhibition of CaMKII showed lower expression of adipogenic markers than in the untreated cells. Treatment of cells with KN-92 had no effect on PPARgamma2 and C/EBPalpha expression. (F) Quantitative analysis of the expression of PPARgamma2, C/EBPalpha, and aP2 levels after CaMKII inhibition (P < 0.01; n = 6). Calcineurin activity is higher in WT ES cells than in calreticulin-deficient cells. (G) At D20, calcineurin activity is higher in WT ES cells than either in calreticulin-deficient (G45crt-/-) cells or undifferentiated ES cells at D0 (n = 4; P < 0.01). (H) Inhibition of calcineurin with cyclosporin A (CsA) increased oil red O staining in 3T3-L1 cells, whereas expression of constitutively active calcineurin decreased oil red O staining. (I) Colorimetric assay of oil red O staining in the 3T3-L1 cells treated as in H (n = 6). 3T3-L1, control; 3T3-L1 + CsA, CsA-treated preadipocytes; 3T3-L1 + CaN, 3T3-L1 cells overexpressing constitutively active calcineurin (CaN). Error bars represent SD.
###end p 34
###begin p 35
###xml 101 127 101 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">Hidaka and Kobayashi, 1994</xref>
###xml 157 160 157 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 160 163 160 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 170 173 170 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt</italic>
###xml 173 176 173 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 234 249 234 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, C and D</xref>
###xml 433 448 425 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, E and F</xref>
###xml 523 538 515 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, C and D</xref>
###xml 585 588 577 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 582 588 574 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 626 641 618 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, E and F</xref>
To elucidate the role of the CaMKII pathway, we used specific inhibitors of CaMKII, KN-62 and KN-93 (Hidaka and Kobayashi, 1994). Inhibition of CaMKII in G45crt-/- and L7crt-/- cells with either KN-62 or KN-93 decreased adipogenesis (Fig. 7, C and D). Inhibition of CaMKII also resulted in the decreased expression of PPARgamma2, C/EBPalpha, and aP2 in all cell lines, with the most dramatic effects in calreticulin-deficient cells (Fig. 7, E and F). KN-92, an inactive analogue of KN-93, did not alter oil red O staining (Fig. 7, C and D) or adipogenic marker expression in either crt-/- or calreticulin-containing ES cells (Fig. 7, E and F). These data suggest that the calmodulin-CaMKII pathway plays an important role during adipogenesis from ES cells.
###end p 35
###begin p 36
###xml 53 77 53 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Neal and Clipstone, 2002</xref>
###xml 79 107 79 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">Kennell and MacDougald, 2005</xref>
###xml 154 170 154 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">Guo et al., 2002</xref>
###xml 172 190 172 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">Lynch et al., 2005</xref>
###xml 308 316 308 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 G</xref>
###xml 416 431 416 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, H and I</xref>
###xml 515 530 515 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7, H and I</xref>
###xml 769 793 769 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">Lynch and Michalak, 2003</xref>
###xml 795 813 795 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">Lynch et al., 2005</xref>
Calcineurin is a negative regulator of adipogenesis (Neal and Clipstone, 2002; Kennell and MacDougald, 2005) and is known to affect calcineurin activity (Guo et al., 2002; Lynch et al., 2005). On D20, calcineurin activity was significantly higher in the WT ES cells than in the calreticulin-deficient cells (Fig. 7 G). In the 3T3-L1 preadipocytes, inhibition of calcineurin with cyclosporin-A promoted adipogenesis (Fig. 7, H and I), whereas constitutive expression of activated calcineurin decreased adipogenesis (Fig. 7, H and I). These data give support for the role of calcineurin in adipogenesis of both ES cells and 3T3-L1 preadipocytes. The present findings are consistent with earlier studies relating activation of calcineurin to the presence of calreticulin (Lynch and Michalak, 2003; Lynch et al., 2005).
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 307 309 307 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 471 473 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 572 574 572 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 619 621 619 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 709 711 709 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 772 774 772 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 880 882 880 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 950 952 950 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 985 987 985 987 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1020 1022 1020 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1120 1122 1120 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1208 1210 1208 1210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1459 1475 1459 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Li et al. (2002)</xref>
###xml 1514 1532 1514 1532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">Grey et al. (2005)</xref>
###xml 1582 1598 1582 1598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Li et al. (2002)</xref>
###xml 1996 1998 1988 1990 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
In this study, we show that calreticulin affects adipocyte differentiation from either ES cells or 3T3-L1 preadipocytes. The absence of calreticulin sways ES cell differentiation toward the adipocyte lineage. This choice of fate is reversed to the WT phenotype by overexpression of calreticulin or by the Ca2+-buffering domain of calreticulin but not by expression of the chaperoning domain of the protein. These effects of calreticulin are likely mediated through its Ca2+ regulatory function. In comparison to WT cells, calreticulin-deficient ES cells have reduced ER Ca2+ storage capacity, resulting in reduced ER Ca2+ release upon stimulation. Expression of full-length calreticulin or the calreticulin Ca2+-buffering domain in ES cells or 3T3-L1 cells increases ER Ca2+ content and reduces the commitment of these cells to adipogenesis. In WT cells, chelating cytoplasmic [Ca2+] enhances adipogenesis, and, conversely, increasing cytoplasmic [Ca2+] inhibits adipogenesis. These Ca2+ effects may negatively affect Ca2+-dependent transcriptional pathways that are required for adipogenesis. Calreticulin exerts its Ca2+ effects within the first 3 d of differentiation, as manipulation of intracellular [Ca2+] at later stages of differentiation (i.e., D7 or D9) did not alter the respective adipogenic potential of ES cells (unpublished data). This is consistent with what has been done to elicit calcium-dependent effects during ES cell differentiation by Li et al. (2002), who used 100 nm ionomycin at D4, and Grey et al. (2005), who used 100 nm ionomycin at D6. Interestingly, Li et al. (2002) showed that ionomycin could be used at concentrations of 10-1,000 nM at days 4-7 with the same effects. Moreover, as calreticulin levels were increasing during the first 3 d of differentiation, PPARgamma2 and C/EBPalpha levels were decreasing, implying that the effects of calreticulin fall within the commitment and/or initial stages of adipogenesis. We conclude that calreticulin may act as a Ca2+-dependent molecular switch that negatively regulates commitment to adipocyte differentiation by down-regulating the expression and transcriptional activation of critical proadipogenic transcription factors.
###end p 38
###begin title 39
###xml 2 4 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Ca2+-handling module of calreticulin inhibits adipogenesis
###end title 39
###begin p 40
###xml 143 145 143 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 161 163 161 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 238 254 238 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">Shi et al., 2000</xref>
###xml 256 275 256 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">Jensen et al., 2004</xref>
###xml 335 337 335 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 462 481 454 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">Jensen et al., 2004</xref>
###xml 509 511 501 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 580 596 572 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib52">Shi et al., 2000</xref>
###xml 636 638 628 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 713 715 705 707 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 819 821 811 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 961 963 953 955 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1067 1069 1059 1061 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1272 1274 1264 1266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
An important finding of this study is that calreticulin, at least in part, exerts its effects on adipogenesis via its role as a modulator of Ca2+ homeostasis. Ca2+ has previously been shown to affect adipogenesis of 3T3-L1 preadipocytes (Shi et al., 2000; Jensen et al., 2004). For example, 3T3-L1 cells exposed to elevated external Ca2+ levels accumulated little or no cytoplasmic lipids and showed the diminished expression of PPARgamma2, C/EBPalpha, and aP2 (Jensen et al., 2004). Increasing cytoplasmic Ca2+ levels by thapsigargin also inhibited early stages of adipogenesis (Shi et al., 2000), all pointing out the importance of Ca2+ on adipogenesis. Indeed, we show here that an increase in intracellular Ca2+ concentration leads to a decrease in adipocyte differentiation. Conversely, decreasing intracellular Ca2+ concentrations promotes adipogenesis of calreticulin-deficient ES cells. The relationship between calreticulin expression, intracellular Ca2+ concentration, and adipogenesis implies that calreticulin exerts its effects on adipogenesis via its Ca2+ homeostatic function. However, the formal proof comes from experiments in which functional modules of calreticulin were expressed in calreticulin-deficient ES cells. Upon expression of calreticulin's Ca2+-buffering P+C domain, adipogenesis was halted, whereas expression of the N+P domain had no effect on the progression of adipogenesis.
###end p 40
###begin p 41
###xml 138 140 138 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 222 237 222 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Li et al., 2002</xref>
###xml 239 256 239 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">Grey et al., 2005</xref>
###xml 257 280 257 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">Puceat and Jaconi, 2005</xref>
###xml 307 325 307 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">Clark et al., 2002</xref>
###xml 370 372 370 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 528 530 528 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 645 647 645 647 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 718 733 718 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Li et al., 2002</xref>
###xml 824 840 824 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Li et al. (2002)</xref>
###xml 286 291 <span type="species:ncbi:9606">human</span>
Our findings that calreticulin affects the commitment to adipocyte differentiation are in line with reports that calreticulin-dependent Ca2+ signaling also affects several aspects of the differentiation of cardiomyocytes (Li et al., 2002; Grey et al., 2005;Puceat and Jaconi, 2005) and human myeloid cells (Clark et al., 2002). Interestingly, diminished intracellular Ca2+ stores attenuate cardiomyogenesis but promote adipogenesis and differentiation of myeloid cells. Combined, these findings imply that calreticulin and ER Ca2+ must play important roles in a variety of differentiation pathways. Moreover, our data regarding timing of the [Ca2+] manipulations indicate that in adipogenesis, as in cardiomyogenesis (Li et al., 2002), there is a calreticulin-regulated calcium-sensitive step referred to as a checkpoint by Li et al. (2002).
###end p 41
###begin title 42
CaMKII and calcineurin activities are crucial for adipogenesis
###end title 42
###begin p 43
###xml 34 36 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 99 116 99 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib56">Wang et al., 1997</xref>
###xml 118 142 118 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Neal and Clipstone, 2002</xref>
###xml 144 172 144 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">Kennell and MacDougald, 2005</xref>
###xml 334 352 326 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">Fajas et al., 2002</xref>
###xml 354 371 346 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib57">Wang et al., 2003</xref>
###xml 373 391 365 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib60">Zhang et al., 2004</xref>
###xml 500 519 492 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">Reusch et al., 2000</xref>
###xml 521 539 513 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">Klemm et al., 2001</xref>
###xml 541 563 533 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">Reusch and Klemm, 2002</xref>
###xml 565 581 557 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">Fox et al., 2006</xref>
###xml 583 609 575 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib55">Vankoningsloo et al., 2006</xref>
###xml 668 692 656 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">Paez-Pereda et al., 2005</xref>
###xml 694 711 682 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">Park et al., 2007</xref>
###xml 894 905 870 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">Rosen, 2005</xref>
Both CaMKII and calcineurin are Ca2+ dependent and have been implicated in affecting adipogenesis (Wang et al., 1997; Neal and Clipstone, 2002; Kennell and MacDougald, 2005). The CaMKII pathway is involved in C/EBPalpha regulation and, thus, indirectly in PPAR regulation. CaMKII activates CREB, which, in turn, activates C/EBPalpha (Fajas et al., 2002; Wang et al., 2003; Zhang et al., 2004). CREB plays a role in adipogenesis, and, indeed, expression of dominant-negative CREB blocks adipogenesis (Reusch et al., 2000; Klemm et al., 2001; Reusch and Klemm, 2002; Fox et al., 2006; Vankoningsloo et al., 2006). CaMKII is also involved in the activation of PPARgamma (Paez-Pereda et al., 2005; Park et al., 2007), indicating that the CaMKII pathway may be critical during adipogenesis. Once C/EBPalpha is expressed, PPARgamma and C/EBPalpha regulate each other, thereby promoting adipogenesis (Rosen, 2005). Here, we show that increased levels of threonine-phosphorylated CaMKII in calreticulin-deficient cells correlate with their increased adipogenesis, and inhibition of CaMKII attenuates adipogenesis in these cells. In calreticulin-deficient cells, in addition to increased CaMKII activity, calmodulin and CREB are also up-regulated, thus explaining the elevated adipogenesis in these cells.
###end p 43
###begin p 44
###xml 14 16 14 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 17 19 17 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ER</sub>
###xml 240 257 240 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">Papp et al., 2007</xref>
###xml 288 306 288 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">Fadel et al., 1999</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">2001</xref>
###xml 314 332 314 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib53">Szabo et al., 2007</xref>
###xml 451 475 451 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">Abdel-Ghany et al., 1990</xref>
###xml 477 503 477 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">Benaim and Villalobo, 2002</xref>
###xml 556 558 556 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 574 593 574 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">Fukami et al., 1986</xref>
###xml 661 679 661 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">Corti et al., 1999</xref>
###xml 813 831 813 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">Meyer et al., 1992</xref>
###xml 962 964 962 964 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Given that [Ca2+]ER is lower in calreticulin-deficient cells, the question arises as to how CaMKII activity could be increased in these cells. In calreticulin-deficient cells, the level of tyrosine phosphorylation, including that of c-Src (Papp et al., 2007), is higher than in WT cells (Fadel et al., 1999, 2001; Szabo et al., 2007). Activated c-Src phosphorylates calmodulin on tyrosine 99, thereby increasing the affinity of calmodulin for CaMKII (Abdel-Ghany et al., 1990; Benaim and Villalobo, 2002). This phosphorylation event is inhibited by high Ca2+ concentration (Fukami et al., 1986). Tyrosine-phosphorylated calmodulin effectively activates CaMKII (Corti et al., 1999). In addition, after initial activation, CaMKII becomes autophosphorylated, remaining active even though its activators are removed (Meyer et al., 1992). Therefore, CaMKII may remain active and promote adipogenesis in calreticulin-deficient cells even under reduced intracellular Ca2+ concentration.
###end p 44
###begin p 45
###xml 319 343 319 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">Neal and Clipstone, 2002</xref>
###xml 345 373 345 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">Kennell and MacDougald, 2005</xref>
###xml 460 462 460 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
We have found that endogenous calcineurin activity was significantly higher in calreticulin-expressing cells that have reduced adipogenic potential compared with the calreticulin-deficient cells that are highly adipogenic. This is in agreement with previous studies on calcineurin-dependent inhibition of adipogenesis (Neal and Clipstone, 2002; Kennell and MacDougald, 2005). Thus, we propose that although the calcineurin pathway inhibits adipogenesis, the Ca2+-independent CaMKII pathway might be responsible for the promotion of adipogenesis in the absence of calreticulin observed here.
###end p 45
###begin title 46
Calreticulin modulates PPARgamma activity through a negative feedback mechanism
###end title 46
###begin p 47
###xml 81 92 73 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">Rosen, 2005</xref>
###xml 169 187 157 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">Rosen et al., 2000</xref>
###xml 243 261 231 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib50">Rosen et al., 2002</xref>
###xml 624 642 604 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">Burns et al., 1994</xref>
###xml 644 663 624 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">Dedhar et al., 1994</xref>
###xml 665 684 645 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib59">Winrow et al., 1995</xref>
###xml 1831 1833 1771 1773 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
PPARgamma2 and C/EBPalpha are crucial transcription factors during adipogenesis (Rosen, 2005); however, although PPARgamma2 is necessary for adipogenesis to take place (Rosen et al., 2000), C/EBP has a more accessory role during this process (Rosen et al., 2002). We showed here that PPARgamma2 and C/EBPalpha are down-regulated in cells overexpressing calreticulin. Therefore, calreticulin may act as a transcriptional regulator of PPAR, whereby it inhibits the binding of PPAR/RXR to PPRE in the promoter region of the target genes, thus inhibiting transcription activation by peroxisome proliferators and by fatty acids (Burns et al., 1994; Dedhar et al., 1994; Winrow et al., 1995). Here, we show that the initial process that precedes the effects of calreticulin on the activity of the PPARgamma-RXR complex involves PPARgamma transcriptional activation of the calreticulin gene. PPARgamma is a potent transcriptional activator of the calreticulin gene as a result of its direct interaction with the calreticulin promoter. Thus, PPARgamma can up-regulate calreticulin, and, conversely, calreticulin can inhibit its activity. We also found an inverse relationship between calreticulin and PPARgamma2 expression upon induction of adipogenesis with RA. RA induces the expression of calreticulin but reduces the expression of PPARgamma2. This supports the notion of a hierarchical process in which transcriptional activation of the calreticulin gene by PPARgamma is the early event followed by calreticulin modulation of PPARgamma transcriptional activity. These data provide evidence for a previously unrecognized negative feedback loop whereby PPARgamma regulates the expression of calreticulin, and calreticulin modulates PPARgamma2 activity and expression. This is likely one important mechanism whereby calreticulin and ER Ca2+ homeostasis regulate adipogenesis.
###end p 47
###begin p 48
###xml 78 80 78 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 183 185 183 185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
In conclusion, for the first time, we show an essential role for organellar Ca2+ in adipogenic regulation. The presence of calreticulin inhibits adipogenesis through its effects on Ca2+ homeostasis, causing the indirect regulation of crucial pathways affecting adipogenesis, such as the calcineurin and CaMKII pathways. Although the CaMKII pathway is important for adipogenic differentiation, the calcineurin pathway may be involved in other choices of fate of ES cells. Finally, we show that the expression of calreticulin is tightly regulated during adipogenesis, and any modification of this expression influences adipogenesis such that aberrant calreticulin expression may lead to a variety of cellular pathologies, including obesity and diabetes.
###end p 48
###begin title 49
Materials and methods
###end title 49
###begin title 50
Cell culture and adipocyte differentiation
###end title 50
###begin p 51
###xml 7 10 7 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 368 388 368 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">Mesaeli et al., 1999</xref>
###xml 666 686 666 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">Mesaeli et al., 1999</xref>
###xml 1088 1091 1088 1091 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1085 1091 1085 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 1215 1218 1214 1217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1212 1218 1211 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 1337 1345 1336 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 1381 1384 1380 1383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1378 1384 1377 1383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 1482 1485 1481 1484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1479 1485 1478 1484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 1500 1503 1499 1502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1497 1503 1496 1502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">crt<sup>&#8722;/&#8722;</sup></italic>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 327 332 <span type="species:ncbi:10090">mouse</span>
G45 crt-/- ES cells and the WT ES cell line (CGR8) were derived from J1 129/Sv mice. To generate the L7 ES cell line, J1 129/Sv ES cells were electroporated with a targeting vector containing the calreticulin gene with the loxP site inserted in introns 1 and 2 (Fig. S1 A) and maintained on mitomycin C-treated G-418-resistant mouse embryonic fibroblast feeder cells (Mesaeli et al., 1999). Recombinant clones were selected with 0.2 mg/ml G418 and 2 mM gancyclovir. Several hundred colonies were picked after 10 d in selection medium and expanded. The L7 clone was selected based on Southern blot analysis and Western blot analysis with anticalreticulin antibodies (Mesaeli et al., 1999). Cre recombinase with additional mutant estrogen receptor ligand-binding domains (Cre-ER and MerCreMer) was used to excise exons 2-4 from the calreticulin gene (Fig. S1 A). In brief, L7 ES cells were stably transfected with Cre recombinase mutant expression vector pANMerCreMER (a gift from J.D. Molkentin, University of Cincinnati, Cincinnati, OH) to generate the L7-Cre cell line. To generate L7crt-/-, 10 muM 4-hydroxytamoxifen was added to promote nuclear translocation and consequently activation of Cre recombinase. L7crt-/- contained a truncated and silenced calreticulin gene with interrupted reading frame and no expression of the protein (Fig. 1 C). Calreticulin-deficient ES (G45crt-/-) cell lines expressing N+P and P+C domains of the protein were also created and designated G45crt-/- N+P and G45crt-/- P+C.
###end p 51
###begin p 52
###xml 301 302 300 301 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 503 505 499 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
Adipocyte differentiation was performed by hanging drop method. In brief, 1,000 ES cells in 20-mul drops were placed on the lids of tissue culture dishes for 2 d. The differentiation medium contained high glucose DME (Multicell; Wisent) supplemented with 15% FBS (Multicell; Wisent), sodium pyruvate, l-glutamine, minimal essential medium nonessential amino acids, and beta-mercaptoethanol. After 2 d, the aggregated ES cells formed EBs, which were floated in differentiation medium supplemented with 10-7 M RA for an additional 3 d. The EBs were then plated onto tissue culture dishes coated with 0.1% gelatin (in PBS) in differentiation medium supplemented with 1 mug/ml insulin and 2 nM triiodothyronine. The differentiation medium was changed every 2 d for the duration of differentiation (15 d). The EBs were then collected for Western blot analysis, RNA isolation, or staining with oil red O.
###end p 52
###begin p 53
###xml 122 143 122 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">Nakamura et al., 2000</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 219 225 <span type="species:ncbi:9913">bovine</span>
Mouse embryonic fibroblasts were isolated from calreticulin-deficient (K42) and WT embryos (K41) as previously described (Nakamura et al., 2000). The 3T3-L1 preadipocyte cells were cultured in DME supplemented with 10% bovine growth serum at 37degreesC. For adipocyte differentiation, 2-d postconfluent cells were cultured for 2 d in differentiation medium containing 1 muM dexamethasone, 0.5 mM methylisobutylxanthine, 5 mug/ml insulin, and 0.5 muM rosiglitazone (Cayman Chemical). Afterward, the 2-d insulin (5 mug/ml) and 0.5 muM rosiglitazone were added. At day 9 of differentiation, the cells were harvested for Western blot analysis, RNA isolation, or staining with oil red O.
###end p 53
###begin title 54
Plasmid DNA and transfections
###end title 54
###begin p 55
###xml 391 412 383 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Nakamura et al., 2001</xref>
###xml 717 738 707 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Nakamura et al., 2001</xref>
pSG5-rRxRalpha and pSG5-mPPARgamma2 were gifts from R. Rachubinski (University of Alberta, Edmonton, Alberta, Canada). Plasmid DNA was purified using Mega plasmid preparation and columns (QIAGEN) as recommended by the manufacturer. Expression vectors encoding the HA-tagged N+P domain (pcDNA3.1_Zeo-CRTNPd-1) and P+C domain (pcDNA3.1_Zeo-CRTPCd-3) of calreticulin were previously described (Nakamura et al., 2001). ES cells were electroporated with 30 mug/cuvette of pcDNA3.1_Zeo-CRTNPd-1 or pcDNA3.1_Zeo-CRTPCd-3 expression vector by electroporation (1,500 V/cm; 25 IxF), and Zeocin (30 mug/ml)-resistant clones were isolated. Expression of the recombinant N+P and P+C domains was monitored with anti-HA antibodies (Nakamura et al., 2001).
###end p 55
###begin p 56
###xml 422 443 421 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Nakamura et al., 2001</xref>
3T3-L1 cells were stably transfected with pcDNA3.1-CRT (encoding HA-tagged full-length calreticulin), pcDNA3.1_Zeo-CRTNPd-1, or pcDNA3.1_Zeo-CRTPCd-3 using Lipofectamine reagent (Invitrogen) according to the manufacturer's instructions. 3T3-L1 clones expressing full-length calreticulin or calreticulin domains were selected with 50 mug/ml Zeocin. Expression of recombinant proteins was monitored with anti-HA antibodies (Nakamura et al., 2001).
###end p 56
###begin title 57
Reporter gene assay
###end title 57
###begin p 58
###xml 416 434 408 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">Waser et al., 1997</xref>
###xml 530 548 522 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">Waser et al., 1997</xref>
###xml 1124 1142 1113 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib58">Waser et al., 1997</xref>
3T3-NIH cells were cotransfected with reporter plasmid containing the calreticulin promoter, deletion of the calreticulin promoter, or the calreticulin promoter with mutations of PPRE1 or PPRE2 (pLC0, pLC1, pLC2, pLC0mt1, and pLC0mt2), PPARgamma, and RXRalpha expression vectors. pLC1 and pLC2 plasmids encode the luciferase reporter gene under the control of 1.7-kb and 0.4-kb calreticulin promoters, respectively (Waser et al., 1997). pLC0 encoded the luciferase reporter gene under control of the 2.1-kb calreticulin promoter (Waser et al., 1997). To generate pLC0mt1 and pLC0mt2 plasmids, site-directed mutagenesis of PPRE1 and PPRE2 of the calreticulin promoter, respectively, was performed using the QuikChange Site-Directed Mutagenesis kit (Stratagene). Specifically, PPRE1 (AGGTCAGAGGACA) was mutated to AGGctcGAGGAtc, whereas PPRE2 (TGGCCCTTGACCT) was mutated to ccGggCTgctCCc (lowercase letters are mutated nucleotides). After 48 h, cells were harvested in a lysis buffer containing 100 mM Tris, pH 7.8, 0.5% NP-40, and 0.5 mM DTT. Luciferase and beta-galactosidase activity were measured as described previously (Waser et al., 1997).
###end p 58
###begin title 59
Inhibitor studies
###end title 59
###begin p 60
###xml 131 157 131 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">Hidaka and Kobayashi, 1994</xref>
At the floating stage (days 3-5 of differentiation), EBs were incubated with KN-62 CaMK inhibitor or its inactive analogue (KN-93; Hidaka and Kobayashi, 1994) at concentrations of 10 muM for 2 h during the 3 d of EB flotation stage. The optimal inhibitory concentrations of KN-62 and KN-93 were determined to be in the range of 10 to 15 muM. Under these conditions, the drugs had no effect on cell survival/proliferation. For inhibition of calcineurin, 3T3-L1 preadipocytes were incubated with 1 mug/ml cyclosporin-A. The cells were then allowed to differentiate for an additional 15 d and were harvested for Western blot analysis, RNA isolation, or staining with oil red O.
###end p 60
###begin title 61
###xml 2 4 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Ca2+ studies and measurements
###end title 61
###begin p 62
###xml 4 6 4 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">45</sup>
###xml 8 10 8 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 38 40 38 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 158 176 158 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">Mery et al. (1996)</xref>
###xml 264 280 264 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">Li et al. (2002)</xref>
###xml 285 303 285 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">Grey et al. (2005)</xref>
###xml 483 485 483 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 604 606 604 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
The 45Ca2+ measurements as well as [Ca2+] measurements using the Ca2+-sensitive fluorescent dye fura-2-AM were performed as previously described in detail by Mery et al. (1996). The ionomycin and BAPTA-AM treatment regimen was performed as previously described by Li et al. (2002) and Grey et al. (2005) with the following modifications: to obtain the optimal functional output, three consecutive pulse treatments were used for either ionomycin or BAPTA-AM. To chelate cytoplasmic Ca2+, floating EBs were incubated with 50 nM BAPTA-AM for 30 min at days 3-5 of differentiation. To increase cytoplasmic Ca2+, the EBs were incubated for 2 h with 500 nM ionomycin in the same manner. Exposure to ionomycin or BAPTA-AM exerts a significant change even after 1 d of treatment, but optimal results were obtained with three pulses of treatment on three consecutive days of differentiation. The cells were then allowed to differentiate on gelatinized (0.01%) tissue culture dishes for 15 d, after which they were collected for Western blot analysis, RNA isolation, or staining with oil red O.
###end p 62
###begin title 63
SDS-PAGE and Western blot analysis
###end title 63
###begin p 64
###xml 167 181 167 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">Bradford, 1976</xref>
###xml 289 310 288 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">Nakamura et al., 2001</xref>
###xml 486 503 481 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">Opas et al., 1991</xref>
###xml 944 955 <span type="species:ncbi:3704">horseradish</span>
Cells were harvested in a lysis buffer containing 50 mM Tris-HCl, pH 8.0, 120 mM NaCl, and 0.5% NP-40. Protein concentration was determined by the method of Bradford (Bradford, 1976). Protein samples (10 mug per lane) were separated by SDS-PAGE and transferred to nitrocellulose membrane (Nakamura et al., 2001). Western blot analysis was performed with the following antibodies: anti-PPARgamma2 (Sigma-Aldrich and Santa Cruz Biotechnology, Inc.) at 1:1,000 dilution; anticalreticulin (Opas et al., 1991) at 1:300 dilution; anti-C/EBPalpha (Santa Cruz Biotechnology, Inc.) at 1:1,000 dilution; anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Labfrontiers) at 1:5,000 dilution; anti-CaMKII (Affinity BioReagents) at 1:1,000 dilution; antiphospho-CaMKII Thr286 (Invitrogen) at 1:500 dilution; anticalmodulin (Affinity BioReagents) at 1:1000 dilution; and anti-CREB pSer133 (Sigma-Aldrich) at 1:1,000 dilution. All secondary antibodies were horseradish peroxidase conjugated (Jackson Immunochemicals) and were used at 1:100,000 dilution. Immunoreactive bands were detected with a chemiluminescence ECL Western blotting system (GE Healthcare). Western blots were normalized by using anti-GAPDH antibodies. Relative mRNA levels were normalized to the housekeeping gene L32. Bands were quantified using ImageJ software (National Institutes of Health).
###end p 64
###begin title 65
RNA preparation and RT-PCR analysis
###end title 65
###begin p 66
Total RNA was isolated from cells grown in 10-cm tissue culture dishes using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. 1 mug RNA was used for synthesis of cDNA followed by RT-PCR using Superscript II (Invitrogen) according to the manufacturer's protocol. The following primers were used for PCR analysis: for PPARgamma, forward primer 5'-ATCAAGTTCAAACATATCACC-3' and reverse primer 5'-TTGTCTTGGATGTCCTCGATG-3'; for C/EBPalpha, reverse primer 5'-CGCAAGAGCCGAGATAAAGC-3' and forward primer 5'-GCGGTCATTGTCACTGGTCA-3'; for aP2, reverse primer 5'-CATCAGCGTAAATGGGGATT-3' and forward primer 5'-TCGACTTTCCATCCCACTTC-3'; and for L32, reverse primer 5'-CATGGCTGCCCTTCGGCCTC-3' and forward primer 5'-CATTCTCTTCGCTGCGTAGCC-3'. PCR products were separated in 1.5% agarose gel. The mRNA levels were normalized using L32 as the housekeeping gene, and relative mRNA levels were quantified using ImageJ software.
###end p 66
###begin title 67
Oil red O staining
###end title 67
###begin p 68
Before staining with oil red O, cells were washed twice with PBS, fixed with 10% formaldehyde for 15 min at room temperature, and washed twice with distilled water and once with 70% isopropanol. Next, cells were stained for 1 h at room temperature with filtered oil red O at a ratio of 60% oil red O stock solution (0.5% wt/vol in isopropanol) to 40% distilled water. The cells were washed twice with distilled water, twice with PBS, and examined under a light microscope. An invertoscope (Diaphot; Nikon) equipped with a 10/0.25 DL dry plan Apochromatic objective (Nikon) was used for imaging at room temperature. A camera (Coolpix 4500; Nikon) was used for image acquisition. For quantitative analysis, oil red O was extracted with 5 ml isopropanol for 2 min, and optical density of each sample was determined at 540 nm.
###end p 68
###begin title 69
EMSA
###end title 69
###begin p 70
###xml 160 176 152 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">Guo et al., 2001</xref>
###xml 258 271 250 263 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AGGTCAGAGGACA</underline>
###xml 317 330 309 322 <underline xmlns:xlink="http://www.w3.org/1999/xlink">TGGCCCTTGACCT</underline>
###xml 437 450 429 442 <underline xmlns:xlink="http://www.w3.org/1999/xlink">AGGTCAAAGGTCA</underline>
###xml 598 600 586 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 698 714 686 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">Guo et al., 2001</xref>
Full-length RXRalpha and PPARgamma and luciferase control proteins were synthesized using a coupled transcription and translation reticulocyte system (Promega; Guo et al., 2001). Synthetic oligodeoxynucleotides corresponding to PPAR site 1 (PPRE1; 5'-AGTGTGGAGGTCAGAGGACACCGGCTC-3') and PPAR site 2 (PPRE2; 5'-TCCTGGCTGGCCCTTGACCTTATCCTG-3') in the calreticulin promoter were used. An ideal PPRE oligodeoxynucleotide sequence, 5'-CAAAACTAGGTCAAAGGTCAAGGCATC-3', was used as a positive control. Underlined residues correspond to the PPAR-binding site. Deoxyoligonucleotides were labeled with gamma-[32P]ATP (GE Healthcare) using T4 polynucleotide kinase. EMSA was performed as described previously (Guo et al., 2001). For supershift analysis, anti-HA tag antibodies were used.
###end p 70
###begin title 71
ChIP assay
###end title 71
###begin p 72
###xml 50 68 50 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">Lynch et al., 2005</xref>
###xml 517 522 <span type="species:ncbi:10090">mouse</span>
ChIP assay was performed as described previously (Lynch et al., 2005). In brief, NIH-3T3 cells were transiently transfected with HA-PPARgamma and cross-linked in 1% formaldehyde at room temperature for 20 min. Cells were then lysed with the Extract-N-Amp kit (Sigma-Aldrich) according to the manufacturer's instructions. Chromatin was sheared by sonication followed by centrifugation for 10 min. Supernatants were precleared with protein A-Sepharose beads for 1 h at 4degreesC. Immunoprecipitation was performed with mouse anti-HA antibodies at 4degreesC overnight. DNA was purified and analyzed by PCR using the following primers: PPRE site 1, forward primer 5'-TGTGTCTGAAGACAGCTACAGTG-3' and reverse primer 5'-GCAGCAGGAGAAAAGAAGAGAG-3'; PPRE site 2, forward primer 5'-CTCTATGGCCTGAACAACTGTG-3' and reverse primer 5'-TGGTCAGAGGGAAGAAGTAAGG-3'
###end p 72
###begin title 73
Calcineurin activity assay
###end title 73
###begin p 74
###xml 66 85 66 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">Fruman et al., 1992</xref>
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 455 457 451 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Calcineurin activity assay was performed as previously described (Fruman et al., 1992). In brief, a peptide corresponding to the regulatory domain of protein kinase A (Sigma-Aldrich) was used as the substrate in an in vitro dephosphorylation assay (RII peptide). 1.0 x 106 cells were lysed in 50 ml hypotonic lysis buffer containing 50 mM Tris, pH 7.5, 0.1 mM EGTA, 1 mM EDTA, 250 mM DTT, and protease inhibitors. 20 ml of lysate was added to 5 mM gamma-[32P]-labeled RII peptide. The reaction was performed for 20 min at 30degreesC in the presence of 0.5 mM okadaic acid with a total reaction volume of 60 ml. The released phosphate reported the activity of calcineurin and was expressed in picomoles of phosphate released per milligrams of total protein.
###end p 74
###begin title 75
Immunofluorescence and Nile red staining
###end title 75
###begin p 76
###xml 331 335 <span type="species:ncbi:9925">goat</span>
###xml 630 636 <span type="species:ncbi:9793">donkey</span>
###xml 642 646 <span type="species:ncbi:9925">goat</span>
Cells on coverslips were fixed in 3.7% formaldehyde in PBS for 10 min. After washing (three times for 5 min) in PBS, the cells were permeabilized with 0.1% Triton X-100 in buffer containing 100 mM Pipes, pH 6.9, 1 mM EGTA, and 4% (wt/vol) polyethylene glycol 8000 for 2 min, washed three times for 5 min in PBS, and incubated with goat polyclonal anti-PPARgamma2 antibody (diluted 1:50 in PBS; Santa Cruz Biotechnology, Inc.) for 30 min at room temperature. After washing three times for 5 min in PBS, the cells were incubated with the secondary antibody for 30 min at room temperature. The secondary antibody was FITC-conjugated donkey anti-goat IgG(H+L) diluted 1:50 in PBS. The cells were then incubated with 0.2 mM ribonuclease A (Sigma-Aldrich) for 2 h at room temperature to digest RNA and washed in PBS (three times for 5 min) followed by incubation with 1 mul/ml propidium iodide in PBS for 30 min to identify nuclei. For Nile red staining, the dye stock solution of 0.5 mg/ml in acetone was diluted in a glycerol/PBS mixture (0.05 ml of Nile red stock solution in 1 ml of 3:1 glycerol/PBS). Cells were fixed and permeabilized as for immunofluorescence and incubated with Nile red working solution for 10 min. After the final wash (three times for 5 min in PBS), the slides were mounted in fluorescent mounting medium (to prevent photobleaching; Dako). A confocal fluorescence microscope (MRC 600; Bio-Rad Laboratories) equipped with a 60/1.40 plan Apochromatic oil immersion objective (Nikon) and a krypton/argon laser was used for fluorescence imaging at room temperature. COMOS software (Bio-Rad Laboratories) was used for image acquisition.
###end p 76
###begin title 77
Statistical analysis
###end title 77
###begin p 78
###xml 123 124 123 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Differences between mean values for different treatments were calculated using analysis of variance or two-tailed unpaired t test (where applicable) and were considered to be significant at P < 0.05 and P < 0.01.
###end p 78
###begin title 79
Online supplemental material
###end title 79
###begin p 80
Fig. S1 shows genomic configuration of the calreticulin gene. Fig. S2 shows nucleotide sequence of the calreticulin promoter. Online supplemental material is available at .
###end p 80
###begin title 81
Supplementary Material
###end title 81
###begin title 82
[Supplemental Material Index]
###end title 82
###begin p 83
The superb technical help of Ewa Dziak is greatly appreciated. We thank Dr. L. Guo for generating the targeting vector with the calreticulin gene flanked by loxP and thank R. Rachubinski and J. Molkentin for plasmid DNA.
###end p 83
###begin p 84
M. Opas is a member of the Heart and Stroke/Richard Lewar Centre of Excellence. This work was supported by grants from the Canadian Institutes of Health Research (CIHR; 36384) and the Heart and Stroke Foundation of Ontario (T6181) to M. Opas and CIHR grants 15415 and 53050 to M. Michalak.
###end p 84

